administer

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

ADDX tokenises private equity fund of funds

Source Node:
Time Stamp: May 11, 2022 6:32 AM - Modified On: May 11, 2022 - Published By:
Source Cluster:
Republished By Plato

The SGX-backed private market exchange has partnered with Fullerton Fund Management to allow tokenised access to the Fullerton Optimised Alpha Fund SINGAPORE, 11 MAY 2022 – Private market exchange ADDX has partnered with investment specialist Fullerton Fund Management Company Ltd (“Fullerton”) to list Fullerton’s private equity fund of funds on its digital platform. The Fullerton Optimised Alpha Fund is a closed-end fund targeting 8% to 12% in returns per annum over its fund life of seven years. The fund will be invested in a portfolio of six to eight private